Condition: IgA Nephropathy (IgAN) · Kidney Diseases · Telitacicept · Sponsor: Ruijin Hospital
A study to evaluate efficacy and safety of telitacicept in the treatment of patients with primary IgA nephropathy at high risk of progression.
This description comes directly from the study's public registry record.
Jingyuan Xie · +86-64370045 · nephroxie@163.com
Always discuss trial participation with your own doctor first.
| Ruijin Hospital | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06654596